Nationwide Class Action Law Firm

  1. Home
  2.  » 
  3. Securities & Investment Fraud
  4.  » Altimmune, Inc.

ALT INVESTOR ALERT: Edelson Lechtzin LLP Urges Altimmune, Inc. (NASDAQ: ALT) Shareholders With Substantial Losses to Seek Legal Counsel In The Pending Securities Fraud Class Action

NEWTOWN, PA, May 13, 2024 — Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of investors in Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) stock between December 1, 2023, and April 26, 2024, inclusive (the “Class Period”).

Investors who purchased Altimmune stock may move the U.S. District Court for the District of Maryland to appoint them as lead plaintiff, no later than July 5, 2024. Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected]. A copy of the class action complaint can be viewed HERE.

Background on AXT, Inc.

Headquartered in Gaithersburg, Maryland, Altimmune is a biopharmaceutical company developing innovative peptide-based therapeutics, including pemvidutide, a dual receptor agonist for obesity and MASH.

The Securities Fraud Claims

The Complaint alleges claims that throughout the Class Period, Defendants made materially false and/or misleading statements regarding the Company’s business, operations, and prospects including that: (i) Altimmune exaggerated pemvidutide’s potential to outperform competing GLP-1 agonists based on the results of the MOMENTUM Trial in terms of efficacy and tolerability.; (ii) Defendants misled investors about the significance of the MOMENTUM Trial results for pemvidutide’s clinical, commercial, and competitive prospects.; (iii) as a result of all the foregoing, Defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide.

On February 13, 2024, Kerrisdale Capital released a report criticizing Altimmune, highlighting that pemvidutide has little chance of competing with existing GLP-1 agonists. The report stated that even if pemvidutide resulted in a 15.6% weight loss, it wouldn’t be enough compared to other approved GLP-1 agonists such as semaglutide (Ozempic) and tirzepatide (Zepbound), which offer better weight loss and blood sugar control. The report also said that pemvidutide has poor tolerability. Kerrisdale concluded that prospective partners were unlikely to invest in pemvidutide because of its perceived shortcomings. On this news, Altimmune’s stock price fell $1.94 per share, or 18.65%, to close at $8.46 on February 13, 2024.

On April 29, 2024, Bloomberg published an article about Altimmune titled, “Altimmune Down as Guggenheim Sees Overhang in No Partnership,” which reported that Guggenheim Securities downgraded Altimmune’s stock from buy to neutral. They expressed doubt about Altimmune’s ability to secure a partnership for their lead asset, pemvidutide, which is intended to treat obesity. Guggenheim suggested that the chance of successfully funding pemvidutide’s development through a strategic partnership was diminishing. They emphasized the absence of a partner just five months away from the end of Phase 2 trials, which indicated a significant challenge in securing funding and market acceptance. On this news, Altimmune’s stock price fell $0.87 per share, or 11.98%, to close at $6.39 per share on April 29, 2024.

For more information, please contact:

Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: [email protected]
Email: [email protected]

Edelson Lechtzin LLP is a leading class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation in cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.

Edelson Lechtzin

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Free Case Review

If you believe you were the victim of securities fraud, click “Join Investigation” below to provide us the information we need to determine your eligibility. If you qualify, someone from our firm will contact you for a free consultation regarding a potential lawsuit to recover your losses.

Join Investigation